Patents by Inventor Qiang Cong

Qiang Cong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230140430
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 4, 2023
    Inventors: Matthew COX, Liqi HE, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Matthias BROEKEMA, Qiang CONG, Daniel O'MALLEY, Yam B. POUDEL, Christine M. TARBY
  • C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230127326
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Christine M. TARBY, Qiang CONG, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Patrice GILL, Prasanna SIVAPRAKASAM, Walter L. JOHNSON, Murugaiah Andappan Murugaiah SUBBAIAH, Yam B. POUDEL
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230130516
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Qian ZHANG, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Qiang CONG, Yam B. POUDEL, Liqi HE, Prasanna SIVAPRAKASAM, Christine M. TARBY
  • Antibody-drug conjugates of tubulysin analogs with enhanced stability
    Patent number: 10279049
    Abstract: The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: May 7, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Sanjeev Gangwar, Vangipuram S. Rangan, Mei-Chen Sung
  • ANTIBODY-DRUG CONJUGATES OF TUBULYSIN ANALOGS WITH ENHANCED STABILITY
    Publication number: 20170326247
    Abstract: The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 16, 2017
    Inventors: Qiang CONG, Sanjeev GANGWAR, Vangipuram S. RANGAN, Mei-Chen SUNG
  • ANTIBODY-DRUG CONJUGATE OF AN ANTI-GLYPICAN-3 ANTIBODY AND A TUBULYSIN ANALOG, PREPARATION AND USES
    Publication number: 20170326249
    Abstract: An antibody-drug conjugate having a structure represented by formula (I) wherein m is 1, 2, 3, or 4 and Ab is an anti-glypican-3 antibody having heavy and light chain CDRs as disclosed herein.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 16, 2017
    Inventors: Chin PAN, Josephine M. CARDARELLI, Haichun HUANG, Sanjeev GANGWAR, Qiang CONG, Karla A. HENNING, Chetana RAO-NAIK, Mohan SRINIVASAN, Vangipuram S. RANGAN, Francis Y. LEE, Ginger C. RAKESTRAW
  • TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE
    Publication number: 20170260232
    Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: May 23, 2017
    Publication date: September 14, 2017
    Inventors: Qiang CONG, Heng CHENG, Sanjeev GANGWAR
  • Tubulysin compounds, methods of making and use
    Patent number: 9688721
    Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
    Patent number: 9580467
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: February 28, 2017
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE
    Publication number: 20160264624
    Abstract: Tubulysin compounds of the formula (I) where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: June 2, 2016
    Publication date: September 15, 2016
    Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
  • Tubulysin compounds, methods of making and use
    Patent number: 9382289
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: July 5, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF
    Publication number: 20160060294
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Application
    Filed: November 12, 2015
    Publication date: March 3, 2016
    Inventors: Heng CHENG, Sanjeev GANGWAR, Qiang CONG
  • Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
    Patent number: 9226974
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: January 5, 2016
    Assignee: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • Tubulysin compounds, methods of making and use
    Patent number: 9109008
    Abstract: Tubulysin compounds of the formula (I) where R1, R2R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: August 18, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE
    Publication number: 20150132324
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: January 26, 2015
    Publication date: May 14, 2015
    Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
  • Tubulysin compounds, methods of making and use
    Patent number: 8980824
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 17, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qiang Cong, Heng Cheng, Sanjeev Gangwar
  • ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES THEREOF, METHODS THEREFOR, AND USES THEREOF
    Publication number: 20140323690
    Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
    Type: Application
    Filed: July 7, 2014
    Publication date: October 30, 2014
    Inventors: Heng Cheng, Sanjeev Gangwar, Qiang Cong
  • TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE
    Publication number: 20140227295
    Abstract: Tubulysin compounds of the formula (I) where R1, R2, R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 14, 2014
    Inventors: Qiang CONG, Heng Cheng, Sanjeev Gangwar
  • TUBULYSIN COMPOUNDS, METHODS OF MAKING AND USE
    Publication number: 20140227298
    Abstract: Tubulysin compounds of the formula (I) where R1, R2R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.
    Type: Application
    Filed: February 11, 2014
    Publication date: August 14, 2014
    Inventors: Qiang CONG, Heng CHENG, Sanjeev GANGWAR